Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[MET receptor inhibition: Hope against resistance to targeted therapies?]

Bulletin du cancer - 1 Feb 2017

Hochart Audrey, Leblond Pierre, Le Bourhis Xuefen, Meignan Samuel, Tulasne David

Abstract excerpt

Overcoming the drug resistance remains a crucial issue in cancer treatment. For refractory patients, the use of MET receptor tyrosine kinase inhibitors seems to be hopeful. Indeed, important mechanisms underlying drug resistance argue for association of MET inhibitors with targeted therapies, both on first-line to prevent a primary resistance and on the second line to overcoming acquired resistance. Indeed, met...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Gene Amplification
Share to Genes, erbB-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-met

Share to Vascular Endothelial Growth Factor A

Source

Identifiers

PMID: 27863726
DOI: 10.1016/j.bulcan.2016.10.014

Genes

MET
BRAF
EGFR
HGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[MET receptor inhibition: Hope against resistance to targeted therapies?]PMID 27863726Read ↗

[Research Progress of Acquired Resistance Mediated by MET Amplification in Advanced Non-small Cell Lung Cancer].Semantic proximity Read ↗

[Drug Resistance Mechanism and Therapeutic Strategy of Targeted Therapy of Non-small Cell Lung Cancer with MET Alterations].Semantic proximity Read ↗

Overcoming resistance to targeted therapy using MET inhibitors in solid cancers: evidence from preclinical and clinical studies.Semantic proximity Read ↗

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer.Semantic proximity Read ↗

<i>MET</i> and <i>KRAS</i> Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase InhibitorsSemantic proximity Read ↗

Management and Treatment of Non-small Cell Lung Cancer with MET Alteration and Mechanisms of Resistance.Semantic proximity Read ↗

MET: a new promising biomarker in non-small-cell lung carcinoma.Semantic proximity Read ↗

The role of MET in chemotherapy resistanceSemantic proximity Read ↗

Cancer therapy: can the challenge be MET?Semantic proximity Read ↗

Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.Semantic proximity Read ↗

[Progress on Mechanism of MET Gene Mutation and Targeted Drugs in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and New Therapeutic Perspectives in Non Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.